Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
NACRES:
NA.23
UNSPSC Code:
12162002
description
typical PEG PDI<1.1; overall PDI≤2.0 (THF, PS)
Quality Level
form
semisolid
feed ratio
lactide:glycolide 75:25
mol wt
PEG average Mn 1,000, PLGA average Mn 2,200, average Mn (1100-1000-1100)
degradation timeframe
2-3 weeks
transition temp
Tm 230-235 °C
PDI
<2.0
storage temp.
2-8°C
General description
PLGA-PEG-PLGA is an amphiphilic triblock copolymer which can self-assemble into micelles in aqueous medium due to the hydrophobic interactions present in the hydrophobic segments. The PEG segment imparts hydrophilicity and improves the biocompatibility of the copolymer. The PLGA segment forms a hydrophobic core and can solubilize hydrophobic drugs. These copolymers are widely used as nanocarriers for the sustained release of drugs.
Application
Used in the synthesis of targeted nanoparticles which are used for differential delivery and controlled release of drugs.
Features and Benefits
Biocompatible, degradable, thermosensitive, high stability, small size (<200 nm) and properties can be easily modified.
Still not finding the right product?
Explore all of our products under Poly(lactide-co-glycolide)-block-poly(ethylene glycol)-block-poly(lactide-co-glycolide)
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Zhimei Song et al.
Journal of colloid and interface science, 354(1), 116-123 (2010-11-04)
The aim of this study was to assess the potential of new copolymeric micelles to modify the pharmacokenetics and tissue distribution of Curcumin (CUR), a hydrophobic drug. In the present study, a poly (d,l-lactide-co-glycolide)-b-poly(ethylene glycol)-b-poly(d,l-lactide-co-glycolide) (PLGA-PEG-PLGA) copolymer was synthesized and
PLGA-PEG Encapsulated sitamaquine nanoparticles drug delivery system against Leishmania donovani
Kumara, R., Sahoo, G. C., Pandeya, K., Dasa, V. N. R., Yousuf, M., Ansaria, S. R., & Dasa, P.
Journal of Scientific and Innovative Research, 3(1), 85-90 (2014)
Frank Gu et al.
Proceedings of the National Academy of Sciences of the United States of America, 105(7), 2586-2591 (2008-02-15)
There has been progressively heightened interest in the development of targeted nanoparticles (NPs) for differential delivery and controlled release of drugs. Despite nearly three decades of research, approaches to reproducibly formulate targeted NPs with the optimal biophysicochemical properties have remained